Cardiovascular and Renal Drugs Advisory Committee
Executive Summary
Will discuss antiarrhythmic guidelines on Oct. 5 and, on Oct. 6, two subjects: the NDA for Riker Labs Tambocor (flecainide) for supraventricular tachycardia, and aspirin for the prevention of myocardial infarction ("The Pink Sheet" July 24, T&G-2). Meeting is scheduled for 9 a.m. at Jack Masur Auditorium at the National Institutes of Health, Clinical Center, Building 10.